Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Mar 10, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific Trans History: 673	Director, President and Chief Scientific	Form 4	Open market or private sale of non-derivative or derivative security	1,159	$461.79	634,455
Mar 09, 2020	YANCOPOULOS GEORGE Director, President and Chief Scientific Trans History: 673	Director, President and Chief Scientific	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	78,376	$476.42	635,614
Dec 16, 2008	YANCOPOULOS GEORGE Director, EVP, CSO, & Pres Regn Res Labs Trans History: 673	Director, EVP, CSO, & Pres Regn Res Labs	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	73,009	$7.41	636,103
Dec 03, 2009	YANCOPOULOS GEORGE Director, EVP CSO & Pres Regn Res Labs Trans History: 673	Director, EVP CSO & Pres Regn Res Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	45,463	$19.29	642,772
Oct 30, 2015	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 673	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	3,806	$559.08	679,012
Dec 13, 2017	YANCOPOULOS GEORGE Director, President & CSO Trans History: 673	Director, President & CSO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	95,050	$385.08	680,612
Oct 30, 2015	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 673	Director, President Regeneron Laboratori	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	182,818	$11.64	682,818
Dec 15, 2016	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 673	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	10,429	$380.09	686,571
Dec 03, 2009	YANCOPOULOS GEORGE Director, EVP CSO & Pres Regn Res Labs Trans History: 673	Director, EVP CSO & Pres Regn Res Labs	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	100,000	$8.77	688,235
Dec 15, 2016	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 673	Director, President Regeneron Laboratori	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	195,079	$20.32	697,000

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media